# OnCo record checkmate-143 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/checkmate-143/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "checkmate-143", "NCT02017717" ;
  schema:name "CheckMate 143"@en ;
  schema:description "CheckMate 143 was the first large randomised test of an immune checkpoint drug in glioblastoma. When the tumour came back, nivolumab kept patients alive no longer than bevacizumab."@en ;
  schema:url <https://onco.cc/trials/checkmate-143/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02017717>, <https://doi.org/10.1001/jamaoncol.2020.1024> ;
  onco:status "negative" ;
  onco:phase "3" ;
  schema:startDate "2014-02-07" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/bevacizumab-glioma/> ;
  onco:terms <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/blood-brain-barrier/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-reardon-jama-oncol/> .